Introduction: Ceftolozane/tazobactam is an
INTRODUCTION
Ceftolozane/tazobactam is an antibacterial agent that shows potent in vitro activity against many extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa, including multidrug-resistant and extremely drug-resistant isolates [1] [2] [3] .
Ceftolozane/tazobactam is approved for the treatment of complicated intraabdominal infections (cIAI) when used in combination with metronidazole and for complicated urinary tract infections (cUTI), including pyelonephritis [4] . In pharmacokinetic (PK) studies, ceftolozane/tazobactam demonstrated dose-dependent, linear PK with no clinically relevant drug accumulation with standard every-8-h dosing [4, 5] . Because ceftolozane/tazobactam is eliminated primarily by the kidneys, dosages must be adjusted to account for impaired renal function, specifically for patients with creatinine clearance (CrCl)
B50 mL/min [4, 6] . The primary objective of this analysis was to simulate the probability of PK/pharmacodynamic (PD) target attainment of ceftolozane/tazobactam in patients with varying degrees of renal impairment, including augmented renal clearance (ARC) and end-stage renal disease (ESRD).
METHODS

Population PK Model for Simulation
In the current analysis, PK/PD target attainment for ARC, normal renal function, and mild, moderate, or severe renal impairment was simulated based on a previously developed population PK model in which CrCl was a significant covariate [7] . The model was developed with the data from ten clinical studies (eight phase 1 and two phase 2 studies) in healthy subjects with normal renal function, subjects with mildly impaired, moderately impaired, or severely impaired renal function, and patients with cUTI or cIAI [7] . These data included the plasma concentrations of ceftolozane and tazobactam that were collected following intravenous administration of ceftolozane/tazobactam, ceftolozane alone, or tazobactam alone. A two-compartment disposition model with zero-order input and first-order elimination best characterized the plasma concentration-time data for both ceftolozane and tazobactam [7] .
PK/PD target attainment for ESRD was simulated based on a previously described population PK model [8] . This model was developed from a PK study in six subjects with ESRD undergoing high-flux hemodialysis (HD) with either Revaclear (Gambro, Stockholm, Sweden) or CT 190G (Baxter Healthcare, McGaw Park, IL, USA) hemodialyzers, and a target adequacy (Kt/V) of at least 1.2 for a minimum of 3 months before enrollment [6] .
Subjects were administered a single dose of ceftolozane/tazobactam without HD (i.e., ceftolozane/tazobactam immediately after HD), followed by a washout period with PK sampling, and then a second dose administered 2 h before a 4-h HD, with intensive PK sampling before and after HD. The collected PK data was then fitted with a nonlinear mixed-effects model with Phoenix NLME software, v.1.2 (Certara L.P. Pharsight, St. Louis, MO, USA). This population PK model is also a two-compartment disposition model to describe the ceftolozane or tazobactam plasma concentration-time data without HD and HD was included as a covariate effect on both clearance and volume of distribution for the central compartment [8] .
Monte Carlo Simulation
Monte Carlo simulations using the population PK models were performed for 1000 patients in each renal function category; 5000 patients were simulated for ESRD. The renal function categories included ARC (CrCl, [150 to B200 mL/min), normal renal function (CrCl, [90 to B150 mL/min), mild renal impairment (CrCl, [50 to B90 mL/min), moderate renal impairment (CrCl, C29 to B50 mL/min), severe renal impairment (CrCl, C15 to \29 mL/min), and ESRD (CrCl, \15 mL/min). These categories of renal impairment were defined before the US Food and Drug Administration (FDA) updated guidance in 2010 [9] , which redefined the cutoff for moderate renal impairment to 30-59 mL/ were simulated for each case, and daily target attainment on day 3 (after the second HD) was the lowest and was reported as a conservative approach.
A finite element method with a time step of 0.001 h was used to simulate the total concentration-time profiles based on the following mass balance differential equations for the population PK model:
where X c and X 2 represent the amount of the drug at time t in the central compartment and peripheral compartment, respectively; R t represents the infusion rate at time t; Cl and Q 2 represent the terminal clearance and intercompartmental clearance between the central and peripheral compartments, respectively; and V c and V 2 represent the volume of distribution for the central and peripheral compartments, respectively. The population PK model parameter estimates were from the previously published population PK models [7, 8, 10] . To explore the situations in which exposures may be lower in some patients than in typical patients or healthy volunteers at the same dose, however, patients with cIAI were assumed for the simulations. This patient group was selected because it was observed that PK exposure in cIAI patients was lower than in non-cIAI subjects (i.e., cUTI patients or healthy volunteers) [7] . In addition, interindividual variability for the parameter estimates in the PK models was conservatively inflated to have a 50% coefficient of variation in the log-scale to cover potentially larger variability in real patients.
PK/PD target attainment by minimum inhibitory concentration (MIC) was assessed for ceftolozane by nonclinical PK/PD targets for simulated patients in each renal function category. As with other cephalosporins, the percentage of time with free drug concentration above the MIC (%fT[MIC) was the PD driver for ceftolozane [11] . The targets for ceftolozane were 24.8% (bacteriostatic), 32.2% (for 1-log kill; bactericidal), and 40% (2-log kill), representing the median %fT[MIC associated with these levels of activity against A b-lactamase-producing strains (n = 12) [15] [16] [17] . Consistent with the IC 50 values from these in vitro enzyme-binding experiments, the tazobactam threshold value was determined to be B1 mg/L across in vitro dose fractionation and in vivo neutropenic mouse thigh infection PD experiments [11, 18] . Additionally, \1 mg/L was found to be fully effective against all ten clinical strains tested [Escherichia coli (n = 6) and [10] for the simulated total concentration-time profiles for ceftolozane and tazobactam, respectively.
Statistical analyses and simulations were performed using SAS 9.2 or 9.3 (SAS Institute Inc, NC, USA).
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PK/PD Target Attainment for Tazobactam
In patients with normal renal function at the 1.5-g ceftolozane/tazobactam dose, the estimated probability of target attainment for 
DISCUSSION
Because ceftolozane/tazobactam is renally excreted, renal function is a significant factor influencing PK, with drug clearance decreasing substantially with increasing renal impairment [7] . Appropriate creatinine measurements that can accurately reflect renal function are critical for dose adjustment, especially at the initial doses. If the baseline creatinine measurement is low, dose adjustment may lead to suboptimal exposure and poor treatment outcome.
Therefore, supporting clinical markers to confirm actual renal impairment (compared with normal renal function) should be considered before a patient receives a reduced dose. As is the case with other cephalosporins, the efficacy of ceftolozane/tazobactam is best correlated with %fT[MIC [11] . Using Monte
Carlo simulations, we showed that the probability of target attainment in the most conservative case is estimated to be C91% for 1-log kill and C82% for 2-log kill bactericidal activity in patients with ARC or mild, moderate, and -cIAI trials [20, 21] , suggesting the validity of the targets.
This study had various limitations. First, although MICs of ceftolozane/tazobactam were determined in the presence of 4 mg/L tazobactam, as recommended by the CLSI [22] , PTA estimates for ceftolozane were based solely on ceftolozane, an approach that has validity for non-ESBL-producing pathogens in patients. 
